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Summary
 
Respiratory syncytial virus (RSV) remains a major cause of morbidity and mortality in infants
and the elderly and is a continuing challenge for vaccine development. A murine T helper cell
(Th) type 2 response associates with enhanced lung pathology, which has been observed in past
infant trials using formalin-inactivated RSV vaccine. In this study, we have engineered an opti-
mized plasmid DNA vector expressing the RSV fusion (F) protein (DNA-F). DNA-F was as
effective as live RSV in mice at inducing neutralizing antibody and cytotoxic T lymphocyte re-
sponses, protection against infection, and high mRNA expression of lung interferon 
 
g
 
 after vi-
ral challenge. Furthermore, a DNA-F boost could switch a preestablished anti-RSV Th2 re-
sponse towards a Th1 response. Critical elements for the optimization of the plasmid constructs
included expression of a secretory form of the F protein and the presence of the rabbit 
 
b
 
-globin
intron II sequence upstream of the F-encoding sequence. In addition, anti-F systemic immune
response profile could be modulated by the route of DNA-F delivery: intramuscular immuni-
zation resulted in balanced responses, whereas intradermal immunization resulted in a Th2 type
of response. Thus, DNA-F immunization may provide a novel and promising RSV vaccina-
tion strategy.
Key words: respiratory syncytial virus • DNA vaccine • vector design • F protein • immune 
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R
 
espiratory syncytial virus (RSV)
 
1
 
 is the principal etio-
logical agent of bronchiolitis and pneumonia in in-
fants and young children worldwide, causing in the USA
alone an estimated 4,500 deaths and 91,000 hospitalizations
annually (1). RSV is also responsible for an estimated 3.3
million cases of respiratory tract diseases in the elderly an-
nually in the USA (2). Thus, there is an urgent need for a
safe and effective RSV vaccine. Protective immunity against
RSV is provided by virus-neutralizing antibodies against the
surface fusion (F) and attachment (G) proteins (3). The con-
served F protein is a cross-protective antigen against both
RSV A and B subtypes (4, 5) and a target for human CTLs
shown to reduce disease severity (6, 7).
RSV has been a difficult vaccination target. Immunity
elicited by primary infection declines rapidly and cannot
prevent reinfection although the severity of the disease de-
creases (3). The development of an RSV vaccine that confers
better protection than natural immunity remains a challenge.
Furthermore, vaccination of infants with a formalin-inacti-
vated (FI)-RSV preparation in the 1960’s did not prevent
RSV disease despite the induction of strong anti-F antibody
responses, and led to enhanced pulmonary disease, even
death, in some vaccinees upon RSV infection (8, 9).
Although the mechanism remains unknown, vaccine-
augmented lung disease may be caused by structurally al-
tered antigens and has been attributed to an imbalanced
cell-mediated immune response of the Th2 type (10). More
recent views of immune effector mechanisms emphasize the
importance of functionally polarized T helper cell subsets
characterized by distinct cytokine repertoires (Th1 and
Th2; reference 11). In the mouse model of RSV infection,
the pattern of pulmonary cytokine response depends on the
nature of the priming immunogen. Enhanced lung pathol-
ogy observed in mice vaccinated with FI-RSV and chal-
lenged with live virus is mediated by CD4
 
1
 
 T cells and is
associated with Th2 cytokines (IL-4, IL-5, and IL-10). In
contrast, immunization with live RSV that does not cause
enhanced lung pathology elicits a mixed Th1/Th2 cytokine
response dominated by IFN-
 
g
 
, a Th1 cytokine (12–15).
 
1
 
Abbreviations used in this paper:
 
 BC cells, Balb/c fibroblasts; DNA-F, opti-
mized plasmid DNA vector expressing the RSV F protein; FI-RSV, for-
malin-inactivated RSV; F protein, fusion protein; RSV, respiratory syn-
cytial virus.
  
682
 
Protection against RSV by DNA Immunization
 
Candidate live attenuated RSV vaccines currently under
evaluation in humans have shown promise in chimpanzees
(16). However, it will be important to assess their risk of
genetic reversion to the wild-type virus. Subunit vaccines
require purification of viral proteins that can lead to dena-
turation, and deleterious immune responses in particular (3)
when formulated in alum, the only adjuvant for human
use, known to induce Th2 responses. The development of
a DNA-based RSV vaccine offers several advantages, in-
cluding its simplicity, the de novo synthesis of properly
folded and glycosylated protein antigens, the ability to in-
duce both neutralizing antibody and cell-mediated re-
sponses, including CTLs, and the possibility to modulate
the pattern of immune responses by the route of DNA ad-
ministration (17, 18). Furthermore, DNA immunization
can elicit lifelong immunity against viruses (19), a highly
desirable property for an RSV vaccine.
The objective of this study was to determine whether
protective immunity against RSV could be elicited by DNA
immunization and to identify elements critical to the success
of this strategy. We found that vaccination of mice with an
optimized plasmid DNA vector expressing the RSV F pro-
tein (DNA-F) induced virus-neutralizing antibodies, CTLs,
protection against viral challenge, and high mRNA expres-
sion of lung IFN-
 
g
 
 after viral challenge. A DNA-F boost
could also switch a preestablished anti-RSV Th2 response
towards a Th1 response. Critical elements for the optimiza-
tion of the plasmid constructs included expression of a secre-
tory form of the protein and the presence of rabbit 
 
b
 
-globin
intron II sequence upstream of the F protein–encoding
sequence. In addition, anti-F systemic immune responses
could be modulated by the route of DNA-F delivery.
 
Materials and Methods
 
Construction of Plasmids Expressing the RSV F Protein.
 
Four plas-
mid vectors (pXL1–pXL4) were constructed to assess the respec-
tive protective abilities of full-length and truncated RSV F pro-
teins in the presence or absence of the rabbit 
 
b
 
-globin intron II
sequence. The 1.6-kb SspI–PstI fragment containing the pro-
moter and intron A sequences of human CMV Towne strain de-
rived from plasmid pRL43a was provided by Dr. G.S. Hayward
(Johns Hopkins University, Baltimore, MD; reference 20) and
was used in all vectors. For the construction of pXL1 and pXL2,
a 1.6-kb EcoRI–BamHI fragment containing the truncated form
of the F cDNA originally cloned from a clinical subgroup A RSV
isolate was excised from plasmid pRSVF (21). For the construc-
tion of pXL3 and pXL4, the full-length F cDNA was excised as a
1.9-kb EcoRI fragment from a recombinant pBluescript M13-SK
containing the F gene insert. The rabbit 
 
b
 
-globin intron II se-
quence derived from pSG5 (Stratagene, La Jolla, CA) was in-
serted upstream of the F protein–encoding sequence in pXL2 and
pXL4. With the exception of the CMV promoter and intron A
sequences, the other vector components (including the bovine
growth hormone poly-A sequence) in pXL1–pXL4, were de-
rived from plasmid pRc/CMV (Invitrogen, San Diego, CA). The
integrity of the F gene and intron II sequences was confirmed by
DNA sequencing.
 
Immunization and RSV Challenge Protocols.
 
Plasmid DNA was
purified using plasmid Mega kits from Qiagen (Chatsworth, CA)
according to the manufacturer’s instructions. For intramuscular
immunization, the tibialis anterior muscles of BALB/c mice
(male, 6–8-wk-old, 8–12/group, from The Jackson Laboratory,
Bar Harbor, ME) were injected bilaterally with 2 
 
3 
 
50 
 
m
 
g (1 
 
m
 
g/
 
m
 
l
in PBS) of a given plasmid. 5 d before DNA injection, the mus-
cles were treated with 2 
 
3 
 
50 
 
m
 
l (10 mM in PBS) of cardiotoxin
(Latoxan, Rosans, France) to increase DNA uptake and enhance
immune responses (22). Animals were boosted 6 wk later with
the same dose of plasmid DNA. For intradermal immunization,
100 
 
m
 
g of pXL2 (2 
 
m
 
g/
 
m
 
l in PBS) was injected near the base of
the tail and boosted 6 wk later with an equivalent dose of plasmid
DNA. Mice in the control groups were immunized either intra-
muscularly with the vector backbone (pXL0), intranasally with
10
 
6
 
 PFU of a clinical RSV strain of the A2 subtype provided by
Dr. B. Graham (Vanderbilt University, Nashville, TN; reference
23), or intramuscularly with an FI-RSV vaccine (100 
 
m
 
l) pre-
pared according to the procedures used for the 1960’s trials (8, 9).
4 wk after the second immunization, mice were challenged intra-
nasally with 10
 
6
 
 PFU of the RSV A2 strain. Lungs were asepti-
cally removed 4 d later, weighed, and homogenized in 2 ml of
DMEM containing 10% FCS and high glucose. The number of
PFU in lung homogenates was determined in duplicate as previ-
ously described (24).
 
Immunogenicity Studies.
 
Immune sera were analyzed for anti-
RSV F antibody titers (IgG, IgG1, and IgG2a, respectively) using
ELISAs and for RSV-specific plaque reduction titers. ELISAs
were performed with an immunoaffinity-purified full-length
RSV F protein (50 ng/ml) using twofold serial dilutions of im-
mune sera. Goat anti–mouse IgG antibody conjugated to alkaline
phosphatase (Jackson ImmunoResearch, Mississauga, Ontario,
Canada) was used as secondary antibody. For the measurement of
IgG1 and IgG2a antibody titers, the secondary antibodies used
were, respectively, monospecific sheep anti–mouse IgG1 (Sero-
tec, Toronto, Ontario, Canada) and rat anti–mouse IgG2a
(Zymed, San Francisco, CA) antibodies conjugated to alkaline
phosphatase. Plaque reduction titers were determined according
to Prince et al. (24). The RSV-specific plaque reduction titer was
defined as the serum dilution yielding 60% reduction in plaque
number. Both ELISAs and plaque reduction assays were per-
formed in duplicate and data are expressed as the means of two
determinations.
 
CTL Studies.
 
Spleens from immunized mice were removed
to prepare single cell suspensions, which were then pooled. Sple-
nocytes were incubated at 2.5 
 
3 
 
10
 
6
 
 cells/ml in complete RPMI
medium containing 10 U/ml of murine IL-2 with 
 
g
 
-irradiated
(3,000 rads) syngeneic splenocytes (2.5 
 
3 
 
10
 
6
 
 cells/ml) infected
with 1 PFU/cell RSV for 2 h. CTL activity was assessed in a
standard 4-h Cr-release assay 5 d after in vitro restimulation. Tar-
get cells were 
 
51
 
Cr-labeled uninfected BALB/c fibroblasts (BC
cells) and persistently RSV-infected BCH4 fibroblasts (25), re-
spectively. Effector cells were incubated with 2 
 
3 
 
10
 
3
 
 target cells
at varying E/T ratios (200 
 
m
 
l, 96-well V-bottomed plates, 4 h at
37
 
8
 
C). Spontaneous and total Cr releases were determined by
incubating target cells either with medium or with 2.5% Triton
X-100 in the absence of effector splenocytes. The percentage of
specific Cr release was calculated as (counts 
 
2 
 
spontaneous
counts)/(total counts 
 
2 
 
spontaneous counts) 
 
3 
 
100. Tests were
performed in triplicate and data are expressed as the means of three
determinations. The experiment was performed three times. To
determine the phenotype of CTLs induced by DNA immuniza-
tion, effector cells were incubated for 1 h with 10 
 
m
 
g/ml of either
a pool of anti-CD4 mAbs (GK1.5 and YTS 177.9; references 26,
27) or a pool of anti-CD8 mAbs (53-6.7, YTS 169 and YTS 
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105.18; references 26, 28) before adding the target cells. To deter-
mine the effect of anti-MHC class I and class II antibodies on CTL
killing, 
 
51
 
Cr-labeled BC or BCH4 cells were incubated either
with 20 
 
m
 
l of culture supernatant from a hybridoma secreting an
anti-H2 class I mAb (34-1-2S) that recognizes both K
 
d
 
 and D
 
d
 
 an-
tigens (29) or with 50 
 
m
 
l of an anti-H2 class II mAb (MK-D6) that
recognizes I-A
 
d
 
 (30) before the addition of the effector cells.
 
Analysis of Cytokine Expression in Lung Tissues.
 
4 d after RSV
challenge, lungs were removed from mice and immediately fro-
zen in liquid nitrogen. Total RNA was prepared from lungs ho-
mogenized in TRIzol/
 
b
 
-mercaptoethanol by chloroform extrac-
tion and isopropanol precipitation. Reverse transcriptase PCR
was then carried out on the RNA samples using IL-4, IL-5, or
IFN-
 
g
 
–specific primers (CloneTech, Mississauga, Ontario, Can-
ada). IL-4 and IL-5 messages were amplified for 25 cycles,
whereas IFN-
 
g
 
 mRNA was amplified for 30 cycles. The ampli-
fied products were then liquid-hybridized to cytokine-specific
 
32
 
P-labeled probes (CloneTech), resolved on 5% polyacrylamide
gels, and quantitated by scanning of the radioactive signals in the
gels. At least three mouse lungs were removed from each treat-
ment group and analyzed for lung cytokine expression a mini-
mum of two times.
 
Statistical Analyses.
 
Data were not distributed normally and
therefore were analyzed using the nonparametric Mann-Whitney
test (SigmaStat software; Jandel Scientific Software, Guelph, On-
tario, Canada). Comparisons were made at a significance level of
0.05 (
 
P
 
 ,
 
0.05).
 
Lung Histopathology Studies.
 
4 d after viral challenge, lungs
from immunized mice were asceptically removed and fixed by
airway perfusion with PBS-buffered formalin. Two hematoxylin
and eosin–stained paraffin-embedded sections were prepared for
each mouse lung. Lungs were sectioned to the largest cross-sec-
tional area. One slide contained the left lung lobes and the other
slide the right lung lobes. Individual slides were then read blindly
in random order and scored using a modification of the proce-
dure described by Murphy et al. (31). In brief, inflammatory infil-
trates of individual bronchioles and pulmonary vessels were
scored from 1 to 6: 1, surrounding space free of infiltrating cells;
2, surrounding space contains few infiltrating cells; 3, surrounding
space contains focal aggregates of infiltrating cells; 4, surrounding
space contains single uninterrupted layer of infiltrating cells; 5,
surrounding space contains two uninterrupted layers of infiltrat-
ing cells; and 6, surrounding space contains three or more unin-
terrupted layers of infiltrating cells.
Slides were uncoded after being scored and values were en-
tered into a computer-based statistics program (SuperANOVA;
Abacus Concepts, Berkeley, CA). Main effects on mean scores
for bronchioles and blood vessels were tested by one-way analyses
of variance. Pairwise comparisons were made using Duncan’s
new multirange test at a significance level of 0.05 (
 
P
 
 ,
 
0.05).
 
Results and Discussion
 
Construction of Plasmid Vectors (pXL1–pXL4) Encoding the
RSV F Protein.
 
To determine if protective immunity
against RSV could be elicited by DNA immunization and
to optimize the DNA vectors, we engineered four plasmid
constructs expressing the RSV F gene under the control of
the immediate-early promoter and intron A sequences of
human CMV and the bovine growth hormone poly-A se-
quence. Plasmids pXL1 and pXL2 were designed to ex-
press a truncated F gene to produce the soluble extracellu-
lar domain of the F protein. Plasmids pXL3 and pXL4
encode the full-length, membrane-anchored F protein. To
circumvent the tendency of RSV F RNA to undergo aber-
rant splicing, we inserted the rabbit 
 
b
 
-globin intron II se-
quence upstream of the F coding region in pXL2 and
pXL4. These plasmids were then tested in mice for their
immunoprotective ability against RSV.
 
Mouse Anti-F Antibody Responses Elicited by pXL1–pXL4.
 
Groups of nine BALB/c mice received bilateral intramus-
cular injections of 100 
 
m
 
g of each individual plasmid, fol-
lowed by a boost 6 wk later. Blood samples were obtained
at 10 wk for antibody measurements. All four F protein–
expressing plasmids (pXL1–pXL4), but not the vector
backbone control (pXL0), induced strong humoral re-
sponses (Fig. 1). Levels of anti-F IgG antibodies reached
endpoint ELISA titers of 5–7 (Log
 
2
 
 titer/100). There was
no significant difference among anti-F IgG antibody levels
elicited by the four F plasmids. Substantial in vitro
 
 
 
RSV-
specific plaque reduction titers (Log
 
2
 
 titers, 9.14–10.88) in-
dicated that the anti-F antibodies induced by pXL1–pXL4
had strong virus-neutralizing activity.
 
Protective Ability of pXL1–pXL4 against RSV in Mice.
 
To assess the protective ability of these vectors, DNA-
immunized mice were challenged intranasally with RSV 4 wk
after the boost and lungs were recovered 4 d later for mea-
surements of virus replication. All plasmids generated pro-
tective immunity, reducing RSV titers by at least 10-fold
compared with pXL0 (Table 1). However, pXL1 encoding
a secretory F protein was 100-fold more effective than
pXL3 encoding the full-length protein. Addition of the
 
b
 
-globin intron II in pXL2 and pXL4 resulted in an increase
of only 1.5-fold in protein expression in vitro (data not
shown). However, the presence of the intron dramatically
enhanced the protective ability of the vectors. No virus
could be detected after RSV challenge in mice immunized
with pXL2 encoding the secreted F protein. Addition of
the intron II also improved the protective immunity in-
Figure 1. Serum antibody responses to pXL1–pXL4 immunization.
Mice were immunized with 100 mg i.m. of pXL1–pXL4 and the vector
control pXL0, respectively, at 0 and 6 wk. Immune sera obtained at 10 wk
were analyzed for both anti-F IgG ELISA and RSV-specific plaque re-
duction titers (RSV-PRT). 
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duced by the plasmid coding for the membrane-bound F
protein by two orders of magnitude (pXL4 versus pXL3).
Thus, the F gene encoding a secreted protein and the pres-
ence of the rabbit 
 
b
 
-globin intron II sequence upstream of
the F gene critically contribute to the protective ability of
the plasmids with only pXL2 conferring full protection.
Our more recent results with pXL2 showed that this vector
could also confer full protection against RSV infection in
mice at a higher infectious virus titer of 5.2 (Log
 
10
 
 PFU/g
lung; data not shown). These findings are consistent with
the emerging evidence that bone marrow–derived APCs
are responsible for immune responses in distal tissues after
intramuscular DNA immunization (32, 33). If this pathway
involves the release of the antigen from myocytes and its
uptake by APCs, it may be advantageous to use secretory
forms of (viral) antigens for DNA immunization.
Although similar levels of neutralizing antibodies were
elicited by pXL1–pXL4, their protective ability differed by
two to three orders of magnitude. Protection against RSV
infection can be adoptively transferred by virus-neutraliz-
ing antibodies (34). However, our results indicate that high
levels of neutralizing antibodies are not always sufficient for
full protection. Vaccination with pXL3 resulted in a strong
neutralizing antibody response but only mediocre reduc-
tion in virus lung titers after challenge. Therefore, other
protective immune effector mechanisms seem to be impor-
tant. To investigate the role of CTLs, pXL2 and pXL3
were compared in mice for the induction of RSV-specific
CTLs. Both vectors were found to elicit comparable CTL
responses at 100-
 
m
 
g doses (data not shown), indicating that
the difference in their protective ability against RSV infec-
tion of the lungs could not be attributed to any difference
in CTL activity. The only difference observed was in the
production of IFN-
 
g
 
 by immune splenocytes. A signifi-
cantly higher IFN-
 
g
 
 response was induced by pXL2 than
by pXL3 (3,327 
 
6
 
 331 pg/ml vs. 1,474 
 
6
 
 591 pg/ml 72 h
after restimulation
 
 
 
in vitro). Treatment of muscle tissue
with cardiotoxin before immunization with DNA-F vec-
tors was found to improve homogeneity of the anti-F anti-
body responses among different mice of the same group.
However, our more recent results indicate that the pre-
treatment step can be eliminated after further modification
of the vector using a more effective signal peptide for en-
hanced F protein expression/secretion (data not shown).
 
Influence of the Route of pXL2 Administration.
 
We next
determined whether the route of pXL2 administration in-
fluenced the immune responses. Intramuscular and intra-
dermal injections of pXL2 led to similar titers of serum
anti-F IgG antibodies and RSV-specific plaque reduction
titers (Table 2, 
 
A
 
). However, intramuscular immunization
induced a mixed systemic Th1/Th2 response characterized
by high levels of anti-F IgG1 and IgG2a antibodies and the
generation of MHC class I–restricted, CD8
 
1
 
 CTLs (Fig. 2),
similar to that observed after RSV infection (Table 2, 
 
B
 
, and
Fig. 2). In contrast, intradermal delivery of pXL2 predomi-
nantly elicited IgG1 antibodies but no CTLs, reminiscent
of the Th2 response induced by FI-RSV immunization
(Table 2, 
 
B
 
, and Fig. 2). Although the serum RSV-specific
plaque reduction titer observed after pXL2 immunization
by either route (mean Log
 
2
 
 titer, 8.60–10.49) was signifi-
cantly lower than that observed after RSV infection (mean
Log
 
2
 
 titer, 12.88), similar lung protection against live RSV
challenge was conferred by all immunizations tested (Table
2). Thus, immune response profiles against RSV can be
modulated by the route of plasmid delivery.
 
Lung Cytokine Response after Viral Challenge.
 
We ex-
pected that the local immune response to RSV challenge
would mirror the systemic response. To test this, lungs re-
covered 4 d after the challenge were analyzed for the ex-
pression (mRNA) of IFN-
 
g
 
, IL-4, and IL-5, the latter con-
tributing to the eosinophil accumulation associated with
enhanced lung pathology (10, 14, 35). Mice immunized
 
Table 1.
 
Immunoprotective Abilities of pXL1, -2, -3, and -4 Plasmids Administered via the Intramuscular Route
 
Immunogen S
 
*
 
M
 
*
 
Intron II
 
*
 
After RSV challenge
Mean virus lung
titer
 
‡ 
 
(Log
 
10
 
 PFU/g)
No. fully protected mice
 
§
 
/
No. immunized mice
pXL1
 
12 2
 
0.72 
 
6
 
 0.99 5/8
pXL2
 
12 1
 
0.00 
 
6
 
 0.00 9/9
pXL3
 
21 2
 
2.77 
 
6
 
 0.72 0/8
pXL4
 
21 1
 
0.66 
 
6
 
 1.00 6/9
pXL0
 
22 2
 
3.93 
 
6
 
 0.27 0/12
Mice were immunized with 100 
 
m
 
g i.m. of either pXL1–pXL4 or pXL0 at 0 and 6 wk and challenged with 10
 
6
 
 PFU i.n. of a clinical RSV strain of
the A2 subtype 4 wk after the boost. Lungs were removed 4 d later to determine the RSV titer.
 
*
 
S, M, and intron II indicate that the F cDNA construct encodes either a secretory (
 
S
 
) or a membrane-anchored (
 
M
 
) form of the protein or contains
the b-globin intron II sequence.
‡Detection sensitivity: 101.96 PFU/g lung.
§Fully protected mice refers to animals with no detectable RSV in lungs after RSV challenge.685 Li et al.
with FI-RSV produced by far the highest IL-4 and IL-5
levels and the lowest IFN-g mRNA levels among all im-
munized animals (Fig. 3), consistent with the systemic and
local Th2 responses previously observed by us and others
(14, 35, 36). In contrast, preimmunization with live RSV
generated a balanced Th1/Th2 cytokine profile, whereas
injection with pXL0 resulted in an overall low cytokine re-
sponse after primary RSV infection. Mice immunized with
pXL2 by either the intramuscular or intradermal route gen-
erated comparable balanced Th1/Th2 cytokine patterns
characterized by a significantly higher IFN-g response than
that induced by live RSV and significantly lower IL-4 and
IL-5 responses than those observed with FI-RSV immuni-
zation (P ,0.05, Mann-Whitney test). Thus, the predomi-
nant systemic Th2 response observed in mice primed by
intradermal pXL2 injection was not predictive of the pul-
monary cytokine mRNA profile.
Lung Histopathology after Viral Challenge. To assess the
degree of lung histopathology induced by pXL2, the inten-
sity of pulmonary inflammatory reactions to live RSV chal-
lenge was analyzed 4 d after the challenge using a standard
scoring system for bronchiolar and vascular cellular infiltra-
tion (31). In mice immunized with pXL0, scores indicative
of very mild cellular infiltrates were significantly lower than
those in the other immunization groups (P ,0.05, Dun-
Table 2. Influence of the Route of Administration on pXL2 Immunogenicity and Protective Ability
Immunogen Route
Mean anti-RSV F ELISA titer
IgG1/IgG2a
Mean plaque
reduction titer
Mean virus
lung titer*
No. fully
protected mice‡/
No. immunized
mice IgG IgG1 IgG2a
Log2 titer/100 1 SD Log2 6 SD Log10 PFU/g 6 SD
A pXL2 i.m. 7.63 6 0.92 4.25 6 1.91 4.00 6 1.71 1.06 10.49 6 0.76 0.00 6 0.00 9/9
pXL2 i.d. 7.35 6 1.00 5.00 6 1.00 0.50 6 1.27 10.00 8.60 6 2.00 0.43 6 1.13 8/9
pXL0 i.m. 0.50 6 0.51 0.00 6 0.00 0.00 6 0.00 0.36 6 0.50 4.30 6 0.22 0/9
B RSV i.n. 9.00 6 0.67 5.00 6 0.82 6.90 6 0.57 0.73 12.88 6 0.34 0.00 6 0.00 9/9
FI-RSV i.m. 7.10 6 0.99 4.60 6 0.97 0.00 6 0.00 infinite 9.20 6 1.10 0.00 6 0.00 9/9
Mice were immunized with pXL2 (100 mg), pXL0 (100 mg), RSV (106 PFU), or FI-RSV (100 ml) at 0 and 6 wk. Immune sera were analyzed at wk
9, 1 wk before the RSV challenge (106 PFU, i.n.). Lung RSV titers were determined 4 d after challenge.
*Detection sensitivity: 101.69 PFU/g lung.
‡“Fully protected mice” refers to animals with no detectable RSV in lungs after RSV challenge.
Figure 2. Characterization of RSV-specific CTLs induced by pXL2.
Mice were immunized with pXL2 (100 mg, i.m. or i.d.), pXL0 (100 mg,
i.m.), RSV (106 PFU, i.n.), or FI-RSV (100 ml, i.m.) at 0 and 6 wk. 4 wk
after the boost, immune splenocytes were stimulated with g-irradiated
syngeneic splenocytes infected with RSV. CTL activity was assessed in a
standard 4-h 51Cr-release assay 5 d later using uninfected BC cells and
persistently RSV-infected BCH4 fibroblasts as targets. To determine the
phenotype of CTLs induced by intramuscular pXL2-immunization, the
effector cells were incubated with pools of either anti-CD4 or anti-CD8
mAbs and the targets with either anti-MHC class I or class II antibodies
(blocking antibodies), respectively, before the CTL assay performed at
100:1 E/T ratio.
Figure 3. Mouse lung cytokine mRNA expression profile after pXL2
immunization. Mice were immunized as in Fig. 2 and challenged intrana-
sally with RSV (106 PFU) at 10 wk. Total RNA was prepared from lung
homogenates 4 d after challenge and subjected to reverse transcriptase
PCR using IL-4, IL-5, or IFN-g-specific primers. The amplified products
were then liquid-hybridized to cytokine-specific 32P-labeled probes, re-
solved on 5% polyacrylamide gels, and quantitated. Data expressed as per-
centage of maximum signal were normalized for each cytokine. Three
lungs were removed from each immunization group and analyzed for cy-
tokine mRNA levels at least twice.686 Protection against RSV by DNA Immunization
can’s new multirange test, SuperANOVA; Table 3). Com-
parable focal peribronchiolar and perivascular cellular ag-
gregates were found in protected animals primed with
RSV, FI-RSV, or pXL2, regardless of the route of deliv-
ery. Eosinophils were not present in any significant num-
ber. Thus, we could not identify animals with enhanced
lung pathology. Our data also indicate that a balanced lung
cytokine response to RSV challenge in mice preimmu-
nized with RSV is associated with the absence of enhanced
histopathology as previously reported by others (14, 31). In
contrast, FI-RSV priming does not necessarily lead to en-
hanced pulmonary inflammatory reactions to live RSV
challenge in mice despite the induction of a strong Th2 re-
sponse in the lungs. This finding is in agreement with prior
observations that it is difficult to document consistent en-
hancement of lung histopathology in mice primed with FI-
RSV and challenged with live RSV (12, 37), and with the
recent finding that other factors such as the phenotype of
effector cells may be important determinants of lung disease
(38). The F protein encoded by the DNA-F vaccine should
be expressed, glycosylated, and folded in the native confor-
mation, yielding an F glycoprotein with its protective
epitopes intact. It was demonstrated that DNA-F immuni-
zation of mice led to balanced lung cytokine expression af-
ter RSV challenge with a stronger dominance of IFN-g
than was observed after vaccination with RSV. Thus, our
data suggest that DNA-F immunization would not lead to
enhanced lung pathology after RSV challenge.
Switch of a Th2 Response towards Th1 by pXL2 Immuniza-
tion. To test whether pXL2 immunization could switch a
preestablished Th2 response towards Th1, we intramuscu-
larly primed and boosted mice with either pXL2 or a vac-
cine preparation containing the native F protein formulated
in alum (Table 4). As expected, pXL2 elicited a balanced
Th1/Th2 response, typified by significant IgG1 and IgG2a
antibody titers and high levels of splenic IFN-g and CTLs.
This pattern was maintained when pXL2-primed mice
were boosted with the alum-adjuvanted subunit vaccine
that by itself induced a Th2 response. Furthermore, a pXL2
boost could switch the Th2 response established in mice
primed with the subunit vaccine towards Th1. These re-
sults are consistent with those obtained with plasmid vec-
tors encoding ovalbumin and b-galactosidase (39).
Collectively, our results reveal distinct differences in mu-
rine immune responses to human RSV, FI-RSV, and plas-
mid DNA-F vaccination. We have demonstrated for the
first time that an optimized RSV F protein–encoding vec-
tor induced high neutralizing antibody titers, CTL re-
sponses, protection against live RSV challenge, and high
expression of lung IFN-g after viral challenge. The DNA-F
vaccine could also switch a preestablished Th2 response to-
wards Th1, a potential advantage in prime-boost immuni-
zation strategies. DNA-F vaccination mimics the immunity
Table 3. Evaluation of Pulmonary Inflammation of Immunized 
Mice after RSV Challenge
Immunogen
Bronchioles Blood Vessels
No. scored Mean 6 SD No. scored Mean 6 SD
pXL2 (i.m.) 262 3.10 6 1.15 390 3.53 6 1.30
pXL2 (i.d.) 287 2.42 6 1.25 330 2.54 6 1.40
RSV (i.n.) 160 3.16 6 0.96 263 4.39 6 1.09
FI-RSV (i.m.) 193 2.36 6 1.08 257 2.62 6 1.26
pXL0 (i.m.) 157 1.35 6 0.60 242 1.45 6 0.87
Mice were immunized and challenged as in Table 2. Lungs were re-
moved 4 d later and fixed with PBS-buffered formalin. Sections from
both the left and the right lobes were scored (from 1 to 6) for inflamma-
tory reactions according to Murphy et al. (31).
Table 4. Switch of Immune Responses From Th2 Towards Th1 by pXL2
Immunogens
IFN-g
Mean anti-RSV F ELISA titer
Prime Boost Total IgG IgG1 IgG2a IgG1/IgG2a
pg/ml Log2 titer/100
pXL2 pXL2 3,887 6.0 6 1.2 2.0 6 0.4 2.6 6 0.6 0.8
pXL2 Subunit-alum 3,238 12.4 6 1.9 9.2 6 0.4 7.2 6 1.2 1.2
Subunit-alum pXL2 1,249 13.0 6 0.8 9.8 6 0.4 7.2 6 1.1 1.4
Subunit-alum Subunit-alum 93 11.2 6 0.5 8.8 6 0.8 0.8 6 1.8 11.0
PBS PBS ND* 00 0
BALB/c mice were primed and boosted intramuscularly with either pXL2 (100 mg) or an alum-adjuvanted RSV subunit preparation containing 0.5
mg of the F protein at 0 and 6 wk. This subunit vaccine was prepared by detergent extraction of a viral concentrate followed by ion-exchange chro-
matography. Immune sera were analyzed at 8 wk for anti-F IgG, IgG1, and IgG2a ELISA titers. The levels of IFN-g production by immune spleen
cells were quantitated by ELISA (PharMingen, Mississauga, Ontario, Canada) after restimulation of these cells with an equal number of g-irradiated,
RSV-infected syngeneic splenocytes for 96 h.
*ND, not detectable.687 Li et al.
elicited by natural RSV infection and thus provides a novel
and promising approach for the development of an effica-
cious human vaccine. However, rational improvement of
the DNA immunization technology is essential for its
eventual success in humans. This is illustrated by the neces-
sity of a rather large dose of DNA vector for full protection
in the mouse model. Improvement of DNA immunization
may be expected by further optimization of expression
vectors and enhanced efficiency of vector delivery, perhaps
in conjunction with targeting of professional APCs (40). It
will also be important to transfer the technology from small
animal models to natural hosts. We are in the process of es-
tablishing an infection model for RSV in monkeys in order
to evaluate the immunogenic and protective properties of
candidate DNA-based vaccines in non-human primates.
Preliminary results to date show significant virus-neutraliz-
ing antibody responses to DNA-F vaccination.
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